NeurAxis Earnings Call Transcripts
Fiscal Year 2026
-
The company reported record Q1 revenue and strong gross margins, driven by expanded insurance coverage and a new Category 1 CPT code. Commercial efforts are focused on pediatric and VA markets, with new hires and resumed commercialization of the RED device supporting growth.
-
Q1 2026 revenue grew 80% year-over-year to $1.6 million, with gross margin expanding to 86.4% and cash burn declining. Commercial focus is on deepening adoption in covered pediatric markets and expanding VA presence, while payer coverage and execution remain key growth drivers.
-
Significant milestones include a new Category I CPT code, expanded insurance coverage, and strong clinical data supporting a non-drug device for pediatric and adult GI disorders. Financials show solid margins and a clear path to profitability, with a focus on scaling coverage and revenue.
Fiscal Year 2025
-
Q4 and FY 2025 saw double-digit revenue growth, major payer wins, and expanded reimbursement access, with strong operational execution and a robust commercial strategy for 2026. Gross margins remained high despite product mix shifts, and liquidity is sufficient for growth plans.
-
Q3 2025 saw 22% revenue growth and the fifth straight quarter of double-digit gains, driven by IB-STIM adoption and FDA label expansion. The new Category 1 CPT code effective in 2026 is expected to accelerate adoption and improve margins, with cash runway into H2 2026.
-
IB-Stim is the first FDA-cleared treatment for pediatric functional abdominal pain and dyspepsia, addressing a major unmet need. With new NASPGHAN guideline support, a Category I CPT code effective January 2026, and expanding insurance coverage, significant market penetration and revenue growth are expected.
-
Q2 2025 saw 46% revenue growth, major milestones including FDA indication expansion, and assignment of a favorable Category I CPT code. Gross margin declined due to discounting, but profitability and cash flow breakeven remain on track as insurance coverage expands and new policies take effect.
-
A neuromodulation company is expanding its pediatric GI therapy indications, supported by strong clinical data, a new Category 1 CPT code effective in 2026, and growing insurance coverage. Recent capital raises ensure over a year of runway as the company prepares for major growth catalysts.
-
Double-digit revenue growth continued in Q1 2025, driven by IB-Stim and RED, with expanding insurance coverage and a new Category I CPT code set to accelerate future growth. Gross margin remains strong, and cash flow break-even is targeted as key academic guidelines and policy coverage are expected soon.
-
The company is at an inflection point, with a category one CPT code effective in 2026, expanded insurance coverage, and strong clinical data supporting its neuromodulation therapies for pediatric and adult GI conditions. Revenue and margins are growing, with new indications and technologies set to drive further expansion.
-
A med tech firm with two FDA indications and a flagship pediatric device is rapidly expanding insurance coverage and achieved a category one CPT code effective January 2026. Q3 and Q4 2024 saw revenue growth of 40% and 50%, with further growth expected as insurance and reimbursement milestones are met.
Fiscal Year 2024
-
Q4 2024 saw 43% revenue growth and expanded insurance coverage to 51 million lives. Category I CPT code and FDA label expansion position the company for accelerated growth, with breakeven targeted at $10–$12 million in annual revenue.
-
Q3 2024 saw 40% revenue growth, a permanent CPT code award, and FDA age expansion for IB-Stim, with RED commercialization expected late 2024. Insurance coverage now reaches 35 million lives, and profitability is targeted for 2025.
-
A pediatric med tech firm is commercializing a non-drug device for GI disorders, supported by strong clinical data and growing insurance coverage. With a robust pipeline, FDA submissions, and a focus on profitability by early 2025, significant revenue growth is anticipated.
-
Q2 2024 saw improved unit sales and insurance coverage progress, though revenue declined 5% year-over-year. Profitability is targeted for Q1 2025, with strong gross margins and a 12-month cash runway supported by recent financing.